Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Proceeds from the funding will be used to support the development of an oral vaccine candidate against Nipah virus (NiV) using the Company’s proprietary OraPro™ thermal stabilization technology.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Department of Health and Social Care
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding February 23, 2022